CG Oncology, Inc. CGON
Updated: 12 Sep 2026
No signal published yet
We already track CG Oncology and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow CG Oncology, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow CG Oncology free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On August 6, 2026, CG Oncology reported its second-quarter 2026 financial results, confirming cash, cash equivalents, and marketable securities of approximately $1.03 billion. The company stated it remains on track to finalize its BLA submission for cretostimogene grenadenorepvec in the fourth quarter of 2026.
What Firelda Watch includes for CG Oncology, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow CG Oncology, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow CG Oncology free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more